Compare Divis Laboratories with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ALKEM LABORATORIES - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ALKEM LABORATORIES DIVIS LABORATORIES/
ALKEM LABORATORIES
 
P/E (TTM) x 49.1 22.0 223.1% View Chart
P/BV x 13.1 5.3 247.3% View Chart
Dividend Yield % 0.5 0.9 50.9%  

Financials

 DIVIS LABORATORIES   ALKEM LABORATORIES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
ALKEM LABORATORIES
Mar-20
DIVIS LABORATORIES/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,6392,720 60.3%   
Low Rs1,1151,660 67.2%   
Sales per share (Unadj.) Rs186.3697.9 26.7%  
Earnings per share (Unadj.) Rs51.096.1 53.0%  
Cash flow per share (Unadj.) Rs57.3117.3 48.9%  
Dividends per share (Unadj.) Rs16.0025.00 64.0%  
Dividend yield (eoy) %1.21.1 101.8%  
Book value per share (Unadj.) Rs261.8515.2 50.8%  
Shares outstanding (eoy) m265.47119.57 222.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.43.1 235.5%   
Avg P/E ratio x27.022.8 118.6%  
P/CF ratio (eoy) x24.018.7 128.6%  
Price / Book Value ratio x5.34.3 123.8%  
Dividend payout %31.426.0 120.7%   
Avg Mkt Cap Rs m365,592261,879 139.6%   
No. of employees `00011.814.3 82.7%   
Total wages/salary Rs m5,42315,055 36.0%   
Avg. sales/employee Rs Th4,175.15,822.6 71.7%   
Avg. wages/employee Rs Th457.71,050.5 43.6%   
Avg. net profit/employee Rs Th1,141.8802.0 142.4%   
INCOME DATA
Net Sales Rs m49,46383,444 59.3%  
Other income Rs m1,5561,042 149.3%   
Total revenues Rs m51,01984,486 60.4%   
Gross profit Rs m18,71814,734 127.0%  
Depreciation Rs m1,6892,528 66.8%   
Interest Rs m35651 5.4%   
Profit before tax Rs m18,55112,598 147.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0231,105 454.7%   
Profit after tax Rs m13,52711,493 117.7%  
Gross profit margin %37.817.7 214.3%  
Effective tax rate %27.18.8 308.8%   
Net profit margin %27.313.8 198.6%  
BALANCE SHEET DATA
Current assets Rs m46,50154,960 84.6%   
Current liabilities Rs m8,46832,433 26.1%   
Net working cap to sales %76.927.0 284.8%  
Current ratio x5.51.7 324.1%  
Inventory Days Days13180 164.4%  
Debtors Days Days8672 119.0%  
Net fixed assets Rs m25,79732,710 78.9%   
Share capital Rs m531239 222.0%   
"Free" reserves Rs m68,96261,368 112.4%   
Net worth Rs m69,49361,607 112.8%   
Long term debt Rs m01,592 0.0%   
Total assets Rs m80,38399,433 80.8%  
Interest coverage x531.020.4 2,607.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.8 73.3%   
Return on assets %16.912.2 138.2%  
Return on equity %19.518.7 104.3%  
Return on capital %26.721.0 127.6%  
Exports to sales %019.1 0.0%   
Imports to sales %24.63.0 828.0%   
Exports (fob) Rs mNA15,917 0.0%   
Imports (cif) Rs m12,1872,483 490.8%   
Fx inflow Rs m41,23816,061 256.8%   
Fx outflow Rs m12,4052,483 499.6%   
Net fx Rs m28,83313,578 212.3%   
CASH FLOW
From Operations Rs m9,5435,851 163.1%  
From Investments Rs m-6,854-7,414 92.5%  
From Financial Activity Rs m-2,459792 -310.7%  
Net Cashflow Rs m230-731 -31.4%  

Share Holding

Indian Promoters % 52.0 66.9 77.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 33.1 35.6%  
FIIs % 19.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 0.0 -  
Shareholders   31,796 68,381 46.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  ELDER PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 25, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS